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Abstract
Background: Microarrays offer great potential as a platform for molecular diagnostics, testing clinical samples for
the presence of numerous biomarkers in highly multiplexed assays. In this study applied to infectious diseases, data
from a microarray designed for molecular serotyping of Streptococcus pneumoniae was used, identifying the
presence of any one of 91 known pneumococcal serotypes from DNA extracts. This microarray incorporated
oligonucleotide probes for all known capsular polysaccharide synthesis genes and required a statistical analysis of
the microarray intensity data to determine which serotype, or combination of serotypes, were present within a
sample based on the combination of genes detected.
Results: We propose an empirical Bayesian model for calculating the probabilities of combinations of serotypes
from the microarray data. The model takes into consideration the dependencies between serotypes, induced by
genes they have in common, and by homologous genes which, although not identical, are similar to each other in
sequence. For serotypes which are very similar in capsular gene composition, extra probes are included on the
microarray, providing additional information which is integrated into the Bayesian model. For each serotype
combination with high probability, a second model, a Bayesian random effects model is applied to determine the
relative abundance of each serotype.
Conclusions: To assess the accuracy of the proposed analysis we applied our methods to experimental data from
samples containing individual serotypes and samples containing combinations of serotypes with known levels of
abundance. All but two of the known serotypes of S. pneumoniae that were tested as individual samples could be
uniquely determined by the Bayesian model. The model also enabled the presence of combinations of serotypes
within samples to be determined. Serotypes with very low abundance within a combination of serotypes can be
detected (down to 2% abundance in this study). As well as detecting the presence of serotype combinations, an
approximate measure of the percentage abundance of the serotypes within the combination can be obtained.
Background
Microarrays are an experimental method for detecting the
presence or absence of multiple genes within a sample
simultaneously, through specific binding to an array of
high-density probes. They therefore have a diagnostic
potential in a number of areas including that of infectious
diseases. A microarray containing probes for genes specific
to different strains of an organism can detect the presence
of a particular strain of the organism in a clinical sample
according to which of the probes have an elevated signal.
Diagnostic testing by microarray is potentially quicker,
easier and more reliable than established tests [1-3]. It also
has the scope for detecting a range of organisms in a sam-
ple in a single test.
A microarray for molecular serotyping of the bacterium
Streptococcus pneumoniae was designed to detect 91
known serotypes of the pneumococcus from DNA extracts
[4]. Clinical samples may contain more than one serotype
of S. pneumoniae. A key feature of molecular serotyping
by microarray, spurring interest in the method, is that
rapid detection of multiple serotypes in a clinical sample
should be feasible. In addition it should be possible to
quantify the relative abundance of each of the serotypes in
the sample. Achieving these two goals with established
serotyping methods is either prohibitively time consuming
or simply not possible. Here we propose a statistical analy-
sis of the S. pneumoniae microarray data that achieves
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both these objectives, identifying both the serotype(s) and
their relative abundance in samples.
The Streptococcus pneumoniae molecular serotyping
microarray was designed with multiple probes represent-
ing all the known capsular polysaccharide synthesis
genes. In the rest of this paper we refer to these genes
as cps genes and these genes’ probes as the CPS probes.
The cps genes encode the proteins and enzymes that
biosynthesise and assemble the capsular polysaccharide.
Serotyping was classically established through cross-
reactivity with typing antisera which discriminate each
serotype due to structural differences in the capsular
polysaccharide. The serotype is relevant because the
capsular polysaccharide represents the interface between
bacterium and host and so is associated with immunity
and invasive disease and forms the basis of polyvalent
vaccines currently available. Each serotype of the pneu-
mococcus contains a small subset of the cps genes, ran-
ging in number from 1 to 22 [5-7], which determines
the nature and structure of the capsule polysaccharide,
and thus the serotype may be determined at the genetic
level by the combination of cps genes present.
For this reason the cps genes have been sequenced for
all 91 serotypes. Most of the serotypes are not fully
sequenced. The design of probes for the array is there-
fore essentially limited to these genes. However, a num-
ber of serotypes may have very similar or even identical
combinations of cps genes present. Therefore additional
probes on the microarray test for more subtle genetic
differences between key cps genes of such serotypes. In
the rest of this paper we refer to these additional probes
as STIDs. One problem that the statistical analysis
needed to address was the integration of the CPS probe
data and the STIDs probe data.
The technique presents several further analysis pro-
blems. Fluorescent intensity signals from microarray
probes for genes indicate gene abundance only indir-
ectly. Such signals are disturbed by a variety of random
factors which are difficult to control: from variation in
the DNA extraction to variation in the binding of the
DNA to its oligonucleotide probe. Concerning the iden-
tification of genes, it is sometimes difficult to design
probes which are entirely specific to a particular gene.
Due to gene homology and the overall similarity of their
DNA sequences, a probe for one gene may bind to the
DNA from a different gene (cross-hybridisation). In
addition, the genomic DNA of the organisms of interest
can be contaminated by DNA from the host and from
other commensal or pathogenic organisms.
In the following we develop an empirical Bayesian sta-
tistical model for calculating the probabilities of serotype
combinations based on the data from the serotyping
microarrays. We first set up likelihoods for gene binding
depending on microarray log intensities for cps genes.
Then, likelihoods of serotype combinations depending
on gene binding and incorporating cross-hybridisation
effects are described. Further, likelihoods for serotypes
depending on log intensities of STID probes are pro-
vided. Finally, all these likelihoods are put together to
give a likelihood of serotype combinations depending on
log intensities from CPS probes and STID probes. Com-
bined with a prior on serotype combinations this allows
us to infer a posterior probability for serotype combina-
tions, apart from a normalising constant. Some of the
hyperparameters of the model are estimated in an
empirical Bayes fashion from the microarray data. Since
there are exponentially many combinations of serotypes,
we use a heuristic to limit the number of combinations
to a subset of serotypes and serotype combinations with
a potential for high probabilities.
The second objective of the analysis is to quantify the
relative abundance of the serotypes in the sample. So in
the final part of the methods section we describe a
Bayesian random effects model for estimating abun-
dances of serotypes for a fixed combination of serotypes.
In order to assess the accuracy of our experimental
and statistical approach, we analysed microarray data
from samples of the 91 known serotypes of the bacter-
ium S. pneumoniae. We refer to these 91 microarrays as
reference arrays. In the first assessment of the method
the task was to detect the single serotype present in the
sample when applied to the 91 reference arrays. Then,
in order to assess the capability of the method to detect
combinations of more than one serotype, four additional
sets of microarray data were produced using a combina-
tion of three or five serotypes in known abundance in a
sample. The latter microarrays, to which we refer as
spike-in experiments, also allow us to assess the accuracy
of the Bayesian random effects model in predicting
abundances of serotypes.
Methods
The first part of the methods section describes the data;
the Streptococcus pneumoniae microarray and the data-
sets used in this article. In the second part we develop a
probabilistic model for calculating the likelihood of a
combination of serotypes given the binding intensities
measured for CPS probes and STID probes on a micro-
array. In the third part of the methods we describe a
Bayesian random effects model for estimating the abun-
dance of each serotype in a combination.
Data
Streptococcus pneumoniae microarray
The BμGS SP-CPSv1.1.0 microarray [4] is a custom
designed microarray on the Agilent SurePrint platform
[8], printed in the 8 × 15K format and comprised primar-
ily of 60mer oligonucleotides probes. These microarrays
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were hybridized as two colour arrays but the two chan-
nels were analysed entirely independently, so that one
array can measure two different samples, one sample
analysed in the red (Cy5) channel and one analysed in
the green (Cy3) channel. This means that the probe
intensity measures used are not intensity ratios but raw
fluorescent intensity values. These values have been
background subtracted at the feature extraction stage
and logs of these intensities are used throughout unless
otherwise stated. Between array normalisation is not
necessary since the data on different arrays, or indeed dif-
ferent channels, are never used in conjunction with each
other for determining the individual serotype call for a
sample.
The microarray contains several thousand oligonu-
cleotide probes designed to detect a number of different
entities:
1. It contains probes, referred to here as CPS probes,
for 432 cps genes. On average there are 10 probes
per gene. These probes are used for serotyping the
sample.
2. It contains probes, referred to here as STID
probes, designed to identify serotypes that are too
closely related to be resolved by the cps genes alone.
3. There are further probes on the microarray for
the entire genome of Streptococcus pneumoniae
from two sequenced strains of the bacterium
(SpTIGR4 and R6), 6824 probes in total, as well as
probes for antibiotic resistance genes and for other
pathogens commonly found in nasopharyngeal
swabs.
The serotype analysis only uses the first two types of
probes directly, the CPS probes and the STID probes,
for calculating the probabilities of combinations of sero-
types. Some of the other probes are used indirectly, in
that the median of the log intensities of the 6824 probes
for the entire S. pneumoniae genome is used to derive
priors for the Bayes calculations in the analysis.
Figure 1 shows a typical boxplot of the CPS probe log
intensities from a microarray testing a sample contain-
ing one serotype. The median of the log intensities
of the 6824 probes on the array for the entire S.
pneumoniae SpTIGR4+R6 genome is also marked on
the figure, as a horizontal dotted line.
Any particular serotype of S. pneumoniae only con-
tains a small subset of the 432 cps genes. In Figure 1
the subset of cps genes found in the serotype being
tested by this example microarray experiment are
marked in black. Some of the cps genes not found in
this serotype have elevated intensities. This reflects
cross-hybridization of probes; in some cases it is difficult
to design probes which are entirely specific to a particu-
lar gene, so probes for one gene may bind to the DNA
from a different gene.
For the 91 serotypes of S. pneumoniae that have been
identified to date, the subsets of cps genes that they con-
tain are known [5,9]. As an example, the cps gene com-
position for a selection of nine of the 91 known
serotypes are shown in table 1. The number of cps
genes present in a serotype varies from as few as 1 to as
many as 22, with an average of 13. In general any two
serotypes will have some cps genes in common. And
some serotypes may have very similar sets of character-
istic cps genes, which makes differentiating between
them more difficult.
In practice a clinical sample may contain more than
one serotype. Figure 2 shows a boxplot of the CPS
probe intensities from a microarray testing a sample
containing five serotypes, 23F, 4, 6B, 14 and 19F, in pro-
portions 50%, 25%, 15%, 8% and 2%. Only the cps genes
found in the five serotypes are shown in the figure for
clarity. It can be seen that some of the cps genes are
found in two or more of the serotypes contained in this
sample. One gene (with serial number 0.01) is found in
all five serotypes. The effect of cross-hybridisation can
also be seen in Figure 2.
A further complexity in the design of the S. pneumoniae
molecular serotyping microarray is that eighteen sets of
closely related serotypes have identical, or nearly identical,
sets of cps genes. An example can be seen in table 1 where
serotypes 35C and 42 have identical gene complements, so
could not be distinguished by CPS probes alone. For such
cases, the microarray contains extra probes in order to dis-
tinguish between the serotypes. The extra probes are here
referred to as STIDs. The serotypes that were targeted by
the STID probes are listed in the first column of table 2.
As can be seen from the table, most STIDs are designed
to differentiate between two serotypes. Such STID probes
for a pair of serotypes come in pairs, with one probe for
one serotype and a paired probe for the corresponding
region of the genome of the second serotype. A STID test
for a pair of serotypes comprises, on average, 65 pairs of
STID probes.
Whilst the STIDs are designed to discriminate specific
pairs of serotypes, in some cases further serotypes, clo-
sely related to the pair in question, will also elevate the
intensities of the STID probes. This is because in the
region of the genome being targeted by the STID
probes, they have identical, or nearly identical
sequences, as one or other of the pair of serotypes in
question. Hence in practice the STID tests are more
complex than indicated in the first column of table 2.
The actual tests being carried out, due to this effect, are
listed in the second column of table 2.
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Datasets used in study
We used two different experimental datasets in order to
validate the probabilistic model described in this article:
1. Reference Arrays: 91 microarrays each testing a
sample containing a single serotype.
2. Spike-in Experiments: four arrays with samples of
more than one serotype. The composition of the
combinations are given in table 3.
The likelihood of a combination of serotypes
The aim is to identify the serotypes present in a sample.
The presence or absence of each of the s serotypes is
indicated by a binary random variable Sj Î {0,1}, 1≤ j ≤ s.
Where s is the number of known serotypes, currently
91. We combine the variables in a binary vector S =
(S1,...,Ss). Depending on the context, S will also denote
the set of indices of present serotypes. Similarly, whether
any gene i of the n genes binds successfully to its CPS
probes is indicated by binary random variables Gi, 1≤ i ≤
n. Where n is the number of cps genes, currently 432. G
denotes the binary vector as well as the set of indices of
binding genes. Each serotype j is associated with a subset
of cps genes known in advance to characterize this parti-
cular serotype (for an example see table 1). We denote
this set of genes by G(j). Similarly, we denote the set of
all the serotypes that contain gene i by S(i).
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Figure 1 Boxplot of CPS probe log intensities for an array testing a sample containing one serotype. Plot of the log probe intensities for
the cps genes from an example of a Streptococcus pneumoniae serotyping microarray experiment testing a sample containing only one serotype.
The serial numbers of the genes are given on the horizontal axis. Only the top 75 genes (out of a total of 432 genes), with the highest mean
probe log intensity are plotted for clarity. The cps genes found in the particular serotype being tested by this microarray experiment are marked
in black. Note that some of the cps genes not expected in this serotype have elevated intensities. This reflects cross-hybridization of probes. The
horizontal dotted line marks the median log intensity of the 6824 S. pneumoniae SpTIGR4+R6 genome probes.
Table 1 Cps gene composition of serotypes
Serotype
35A 0.01 1.01 2.01 3.01 5.01 16.01 45.01 128.01 129.01 130.02 131.01 51.01 132.01 7.01 21.01 6.01 18.01
35C 0.01 1.01 2.01 3.01 5.01 16.01 45.01 128.01 129.01 130.01 131.01 51.01 132.01 7.01 21.01 6.01 18.01
42 0.01 1.01 2.01 3.01 5.01 16.01 45.01 128.01 129.01 130.01 131.01 51.01 132.01 7.01 21.01 6.01 18.01
35B 0.01 1.01 2.01 3.01 5.01 16.01 45.04 129.03 117.02 51.04 7.16 21.02 6.02
35F 0.01 1.01 2.02 3.02 61.01 16.03 45.02 46.01 24.01 32.01 7.08 21.02 6.02
36 0.01 1.02 2.02 3.02 5.02 46.03 33.04 66.02 23.05 25.07 7.17 254.01 6.04 51.05
38 6.04 2.03 3.04 0.02 1.03 29.02 170.01 171.01 172.01 173.01 174.01 187.01 176.01 177.01 96.01 20.03
39 0.01 1.02 2.04 3.05 61.01 16.04 149.02 44.03 24.06 32.04 25.08 67.02 102.02 7.18 6.04 80.01
4 0.01 1.01 2.02 3.02 261.01 29.04 35.02 212.01 30.03 213.01 214.01 215.01 23.06 36.01 37.01 38.01
The cps gene composition for a selection of nine of the 91 known serotypes of Streptococcus pneumoniae [5]. The entries in the table are serial numbers for
individual cps genes.
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The likelihood of the combination of serotypes con-
sists of three parts enumerated below:
1. Likelihood of a gene binding depending on CPS
probes. We denote the set of log intensities of CPS
probes for cps gene i by yi, 1≤ i ≤ n. The vector y =
(y1,...,yn) denotes the data sets for all the cps genes
on the microarray. This part describes the likelihood
of gene i binding depending on its probes yi.
2. Likelihood of a serotype combination depending on
gene binding. Each serotype is defined by a charac-
teristic subset of cps genes. The subsets of cps genes
of different serotypes might partly be identical. In
addition genes occurring in the characteristic subsets
of genes of two different serotypes may be very simi-
lar (homologous) to each other, resulting in cross-
hybridisation. These dependencies between serotypes
need to be taken into account. This part describes
the likelihood of a serotype combination S depend-
ing on genes binding and the grouping of genes
according to homology.
3. Likelihood of a serotype combination depending on
STID probes. In order to help with the differentiation
between serotypes with identical or very similar sets
of cps genes, additional probes are added to the
microarrays, the STID probes. Each set dl, 1 ≤ l ≤ L,
of STID probes is designed to differentiate between
two serotypes (or more generally, two groups of ser-
otypes). The vector d = (d1,...,dL) denotes all the
STID data from a microarray experiment. This part
describes the likelihood of a serotype combination S
depending on STID probes d.
These three likelihoods are explained in the following
three sections. The fourth section, combines the above
likelihoods into P(y, d |S) for a serotype combination S
and data y, d. This likelihood can be evaluated for any
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Figure 2 Boxplot of CPS probe intensities for an array testing a sample containing five serotypes. Plot of the probe intensities for the cps
genes from an example of a Streptococcus pneumoniae serotyping microarray experiment testing a sample containing five serotypes. The serial
numbers of the genes are given on the horizontal axis. Only the cps genes found in the five serotypes are plotted for clarity. The horizontal
dotted line marks the median log intensity of the 6824 S. pneumoniae SpTIGR4+R6 genome probes. The genes are colour-coded to indicate in
which serotype or serotypes they occur.
Table 2 STID tests
STID tests Actual STID tests
11A_vs_11D 11A_vs_11D+11F
11B_vs_11C 11B_vs_11C+11A+11D
12A+12B_vs_46 12A+12B+12F+44_vs_46
12A+46_vs_12B 12A+46_vs_12B+12F+44
12F_vs_44 12F+12A+12B+46_vs_44
15B_vs_15C 15B_vs_15C
18B_vs_18C 18B_vs_18C+18A+18F
22A_vs_22F 22A_vs_22F
25A_vs_25F 25A_vs_25F
28A_vs_28F 28A_vs_28F
32A_vs_32F 32A_vs_32F
33A_vs_33F 33A+37_vs_33F
35C_vs_42 35C+35A_vs_42
40_vs_7B 40+7F_vs_7B+7C
7A_vs_7F 7A_vs_7F
9A_vs_9V 9A_vs_9V+9L+9N
9L_vs_9N 9L+9A+9V_vs_9N
6A_vs_6B 6A+6C_vs_6B+6D
The STID tests designed to discriminate identical or very similar serotypes and
the actual STID tests carried out in practice.
Newton et al. BMC Bioinformatics 2011, 12:88
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combination S of the 91 serotypes. Since this is imprac-
tical for all 291 possible combinations, we resort to using
a heuristic to select a subset of combinations of sero-
types. We also suggest a prior P(S) in this section.
The prior P(S) and likelihood P(y, d |S) for S allow us
to calculated the posterior P(S |y, d) apart from a nor-
malising constant
P
(
S|y, d) ∝ P (y, d|S)P (S)
Likelihood of a gene binding depending on CPS probes
Each cps gene i is represented by a set of about ten CPS
probes with log intensities yi =
(
yi,1, ..., yi,ri
)
, where ri is
the number of probes on the array for gene i. Assume
the true log intensity value for binding of a gene i is μi,
with yi,r ∼ N(μi, σ 2i ). We simplify notation by setting
pN(yi | μi, σ 2i ) =
∏
r pN(yi,r | μi, σ 2i ). If Gi = 1, that is,
binding is successful, then μi >m, where m is the log
intensity of the background signal due to unspecific
binding. If Gi = 0, that is, binding is unsuccessful, then
μi = m. Since we have little information about μi, m,
and σ 2i we consider them to be nuisance parameters
over which should be integrated. Assuming reasonable
priors for these parameters we can calculate P(yi |
Gi = 0) and P(yi | Gi = 1) as follows.
In general, visual inspection of distributions of log
intensities suggests that assumptions of Gaussian distri-
butions on the above parameters might not oversimplify
matters too much (see Figure 3 for an example of a
typical distribution). This is also the standard assump-
tion in much of the analysis of log intensity values from
microarray experiments in the literature [10].
As priors for μi, m, and σ 2i we assume:
1. σ 2i ∼ Inv-χ2(ν0,ρ20), a scaled inverse c2 distribu-
tion with shape and scale parameter ν0 and ρ20 (for
details see Additional file 1).
2. m ∼ N(μ0, σ 20 ), where μ0 and σ 20 are the prior
mean and variance of the background distribution of
log intensity values.
3. μi = m if Gi = 0, and μi | σ 2i ∼ N(μ(1), σ 2i /κ1) and
μi >m if Gi = 1, where μ(1) is the prior mean for the
log intensity signal of the probes when a gene binds,
and 1 is a prior scaling factor for the variance.
For Gi = 0 we obtain the likelihood
p(yi | Gi = 0) =
∫ ∫
pN(yi|μ, σ 2)pICh(σ 2|ν0,ρ20)
d(σ 2)pN(μ|μ0, σ 20 )dμ
=
∫
p1(yi|μ, ν0,ρ20)pN(μ|μ0, σ 20 )dμ
(1)
Here p1(yi|μ, ν0, ρ20) is a multivariate t distribution as
in equation 2 in Additional file 1. The integral over μ is
solved numerically. Similarly, for Gi = 1 we obtain
p(yi | Gi = 1) ∝
∫ ∫
I(μ > m)
∫
pN(yi | μ, σ 2)
pN(μ | μ(1), σ 2/κ1)
pICh(σ 2 | ν0,ρ20)
d(σ 2)pN(m | μ0, σ 20 )dm dμ
=
∫
p2(yi,μ | μ(1), κ1, ν0,ρ0)∫ μ
−∞i
pN(m | μ0, σ 20 )dm dμ
=
∫
p2(yi,μ | μ(1), κ1, ν0,ρ0)
N(μ | μ0, σ 20 )dμ
(2)
where I is an indicator variable for an event, and p2(yi,
μ|μ(1) 1, ν0, r0) is a multivariate t distribution as in equa-
tion 4 in Additional file 1. The integral over μ is solved
numerically: the ‘int’ function of the R [11] package ‘rmu-
til’ [12] was found to be a reliable option for evaluating
these equations with the given data. Equation 2 is normal-
ised by a factor obtained by a similar numerical integration
where the term pN(yi|μ, s2) is dropped.
Constants for the prior distributions were chosen
using statistics from the arrays, so that the above
approach is a test of hypotheses via an empirical Bayes
procedure:
1. For the Gaussian prior on background signal
m ∼ N(μ0, σ 20 ) we set the mean μ0 to the mode of
Table 3 Spike-in experiment
Sample Serotypes % Abundance Estimated % Abundance
1 19F, 18C, 9V 33, 33, 33 25(10, 39), 36(23, 50), 39(28, 49)
2 19F, 18C, 9V 60, 30, 10 40(25, 55), 38(24, 53), 22(9, 34)
3 23F, 4, 6B, 14, 19F 20, 20, 20, 20, 20 26(14, 39), 12(1, 23), 21(8, 33), 25(13, 37), 16(3, 29)
4 23F, 4, 6B, 14, 19F 50, 25, 15, 8, 2 49(34, 64), 17(4, 29), 15(3, 29), 14(0, 26), 5(0, 20)
The serotype combinations and percentage abundances used in the spike-in experiment and the results of the data analysis. The figures in brackets following
the estimated % abundance πi are the lower and upper 95% credible intervals.
Newton et al. BMC Bioinformatics 2011, 12:88
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all the log intensities on the array. The scale para-
meter σ 20 was set to the 0.33 quantile of all log
intensities below the mode. This seems to capture
the overall distribution of unspecific signals. Figure 3
shows the density distribution of the data plotted in
Figure 1, with the background prior distribution
N
(
μ0, σ 20
)
superimposed.
2. The prior mean μ(1) for the log signal intensity
was set to the median of the data from the 6824
probes on the array for the entire S. pneumoniae
SpTIGR4+R6 genome. This genome provides a stan-
dard reference level for a binding signal, but is actu-
ally independent of the binding of the cps genes in
our model. The value of the prior mean for the log
signal intensity μ(1) is marked on Figure 3.
Two values were used for the prior scaling factor for
the variance 1. For increased specificity, that is, less
chance of false positives, but with a concomitant
increase in false negatives, a value of 1 = 13 was
used, which is the average number of genes of a ser-
otype. For increased sensitivity, that is, fewer false
negatives, but possibly more false positives, a value
of 1 = 1 was used.
3. The shape parameter ν0 of the variance prior
σ 2i ∼ Inv-χ2(ν0,ρ20) was set to 1 in all cases to give
a reasonably broad prior distribution on the noise
variance. The scale parameter r0 of the variance
prior is calculated as 1/4 of the distance between μ0
and μ(1).
Likelihood of a serotype combination depending on gene
binding
If any one of the serotypes S(i) containing gene i is pre-
sent, we expect Gi = 1, that is, gene i binds to its
probes. We assume that the binding might fail with
small probability b for one serotype. The reason may be
experimental failure or biological variation. For simpli-
city we further assume that these failures are indepen-
dent for each serotype. Hence the probability that a
gene i fails to bind is bk, where k =
∣∣S(i) ∩ S∣∣ is the
number of serotypes present in the sample and contain-
ing gene i. On the other hand, there might be a small
probability a of a spurious binding response. After con-
sultation with experimentalists, these parameters are
assumed to be around a = b = 0.01 (see the results sec-
tion for maximum likelihood estimations of these
values).
Some of the cps genes are evolutionarily closely
related (homologous) [6,7]. Their DNA sequences may
be quite similar. The intensities of the probes for a
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Figure 3 Density estimate of CPS probe intensities. Density estimate of the log probe intensities for 432 cps genes from a Streptococcus
pneumoniae serotyping microarray testing strain 24A. The background prior distribution N
(
μ0, σ 20
)
and the value of the signal prior mean μ(1)
for this data are also shown. The inset shows the signal part of the distribution in more detail.
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particular gene may be elevated not by the presence of
the gene they were designed to target, but by the pre-
sence of a homologous gene. The probes on the array
have been designed to minimize cross-hybridisation, and
in practice we find that the signal for most genes are
independent. There is however a subset of 30 genes in 9
different homology groups where there is significant
cross-hybridisation. We consider these 30 genes as
belonging to 9 cross-hybridisation groups, and the
remaining 402 genes as belonging to 402 groups con-
taining just one gene. We assume a constant probability
g that a gene wrongly appears as present due to the pre-
sence of another gene in the same cross-hybridisation
group. After consultation with experimentalists we set
the value of g to 0.95. A maximum likelihood estimation
of g is presented in the results section.
For the sake of brevity denote the set of genes present
in a set of serotypes by G(S) = ∪{G(j)|Sj = 1}. The bin-
ary variable Hk indicates the presence of a representative
gene of cross-hybridisation group k in G(S). ℋ(k) is the
index set of genes belonging to group k. When a sero-
type is present with a gene from the hybridisation
group, that group counts as present:
P(Hk = 1|S) =
{
1 ifH(k) ∩ G(S) = ∅
0 else
(3)
For i Î ℋ(k) we have
P (Gi = 1|Hk, S)
=
⎧⎪⎪⎨
⎪⎪⎩
1 − β |S(i)∩S| if Hk = 1 and i ∈ G (S)
γ if Hk = 1 and i /∈ G (S)
0 if Hk = 0 and i ∈ G (S)
α if Hk = 0 and i /∈ G (S)
(4)
Note that in the third condition Hk = 0 means that no
member of the cross-hybridisation group ℋ(k) is pre-
sent, in contradiction to gene i being a member (i Î ℋ
(k)) and being present (i ∈ G(S)); the corresponding
probability can be set to any arbitrary value, say 0.
Likelihood of a serotype combination depending on STID
probes
A number of pairs of serotypes have identical cps gene
complements. In order to distinguish between these ser-
otypes the microarray contains extra oligonucleotide
probes which test subtle genetic differences between key
cps genes of these serotypes. These extra probes are
referred to as STIDs.
STID probes are different from the CPS probes in that
they enable a direct comparison of two specific sets of
serotypes: a set Tl of STID probes is designed to show
the presence or absence of any serotype of a set T(1)l of
serotypes compared to presence or absence of any sero-
type of another set T(2)l of serotypes. The STID probes
for T(1)l and T
(2)
l
are paired, that is, each probe for one
serotype set has a corresponding probe for the other
serotype set. We analyse the difference of values of the
paired probes. For a set Tl of STIDs we denote the mea-
sured differences in log intensities by dl. Similar to
equations 1 and 2 we define
p3(dl|ν2,ρ22 , σ 22 ) =
∫
p1(dl|μ, ν2,ρ22)
pN(μ|0, σ 22 ) dμ
p4(dl|μ2, κ2, ν2,ρ22 , σ 22 ) ∝
∫
p2(dl,μ|μ2, κ2, ν2,ρ22)
N(μ|0, σ 22 ) dμ
where p1(dl|μ, ν2,ρ22) and p2(dl,μ|μ2, κ2, ν2,ρ22) are as
defined in equations 1 and 2; they can be expressed ana-
lytically as in equation 2 and 4 in Additional file 1. We
obtain for the distribution of differences between log
intensities of STID probes
P (dl|S)
=
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
p3 (dl|ν2,ρ22 , σ 22 )
if either some serotypes of bothT(1)l
andT(2)l are present or none of them
p4(dl|μ2, κ2, ν2,ρ2, σ 22 )
if atleast one serotype ofT(1)l
present and allT(2)l absent
p4(−dl| − μ2, κ2, ν2,ρ2, σ 22 )
if atleast one serotype ofT(2)l
present and all T(1)l absent
(5)
After inspection of typical differences in log intensities
of STID probes we use prior values μ2 = 0.5, ρ22 = σ
2
2 =
ν2 = 2 = 1
Posterior of combinations of serotypes
The likelihood of a given serotype combination is given
by combining equations 1, 2, 3, 4, and 5
P(y, d | S) =
∏
k
∏
i∈H(k)
(
∑
Hk=0,1
(
∑
Gi=0,1
P(yi|Gi)
P(Gi|Hk, S))P(Hk|S))
∏
l
P(dl|S)
This model is represented schematically in Figure 4.
In practice there are too many different serotypes S,
currently 91, to calculate P (y, d | S) for all possible 291
combinations. The question is whether we need to test
all possible combinations of serotypes. In principle some
higher order combination of serotypes might show an
unexpectedly high probability, higher than any of its
Newton et al. BMC Bioinformatics 2011, 12:88
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subsets, for example, due to the cross hybridisation
effect. However, here we assume that such cases are
rare. The observation that in clinical samples a combi-
nation containing more than three serotypes is highly
unusual provides a further justification for this
assumption.
Therefore we try to catch at least all pairwise interac-
tions by calculating P (y | S) for all S with at most two
serotypes. We assume it is unlikely that higher order
interactions are not visible in at least pairwise interac-
tions. The serotypes from the thirty most probable of
these pairwise combinations are pooled and used to cal-
culate P (y | S) for all possible combinations of three or
fewer serotypes out of the pool, thus allowing for some
high probability three-way interactions that have less
probable two-way interactions. Finally, serotypes of the
fifteen most probable combinations from this pool are
selected to create a final pool of serotypes that is small
enough to allow calculation of the probability of combi-
nations of eight or less serotypes from the pool.
In order to calculate the posterior P (S | y, d) from the
likelihood we require a prior P (S). Let P(l) denote the
prior probability of being infected by a number of sero-
types l out of a total of s = 91 possible serotypes. Since
there are
(
s
λ
)
serotype combinations with l serotypes
this implies a prior P(S) of
P (S) = P (λ (S))
(
s
λ(S)
)
where l(S) is the number of serotypes in S. The prob-
ability P(l) is probably declining rapidly with l. Since
the exact distribution is unknown, we assume for sim-
plicity that this probability is constant P(l) = 1/(s + 1)
for all l (including the possibility that no serotype is
present). Prior and likelihood for S allow us to calcu-
lated the posterior P(S | y, d) apart from a normalising
constant
P
(
S|y, d) ∝ P (y, d|S)P (S)
The software implementation of the analysis method
normalises P(y, d | S)P(S) for a particular set of combi-
nations of serotypes S, using the sum of P(y, d | S)P(S)
from all the combinations of serotypes chosen according
to the above selection heuristic. Since these combina-
tions seem to capture most of the posterior probability
mass for S we take these normalised values as approxi-
mation to the posterior P(S | y, d).
Proportional abundance of serotypes
If the analysis detects the presence of more than one
serotype within a sample then information on the rela-
tive abundance of the serotypes is desirable. Each sero-
type is represented by a selection of genes, whose
abundance can be measured. This suggests an ANOVA
analysis to estimate abundance of serotypes. Again we
opt for a Bayesian treatment which allows us to inte-
grate out nuisance variables such as gene specific effects
and to derive credible intervals for the serotype abun-
dance estimates.
For the following analysis we work with raw intensities
without log transformation since serotype presence and
abundance will have an additive effect on gene specific
intensities. For obtaining an analytical solution, a linear
STID Probe Intensities d1
SEROTYPES S1 S2 S3 S4
CPS Cross-Hybridisation groups H1
CPS Genes G1 G2 G3 G4
CPS Probe Intensities y1 y2 y3 y4
Figure 4 An example of a model for serotype combinations showing independence relationships as a graphical model. The binary
variable Si indicates the presence/absence of serotype i, the binary variable Gj that of gene j, and yj a set of log intensities from the CPS probes
representing gene j. Binary variable Hk indicates the presence of a representative gene of cross-hybridisation group k. dl indicates a set of log
intensities from the STID probes (square boxes indicate data).
Newton et al. BMC Bioinformatics 2011, 12:88
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model with untruncated Gaussian distributions as error
and prior distributions is convenient. Since intensities
can only be positive such a model can only be consid-
ered an approximation. A further problem is that the
variance of a variable measuring abundance is often not
constant and depends on the size of the variable. This is
mitigated to some degree by integrating over variances
in the Bayesian model. Despite its shortcomings, the
results indicate the model reproduces experimental data
reasonably well.
More specifically, we want to estimate the proportion
of b serotypes in the sample. Each serotype is repre-
sented by a set of genes as specified in a g × b binary
0/1 matrix G, where g is the number of genes involved.
We assume that gene abundance as reflected in its
probe intensities is linearly related to the sum of the
abundances of serotypes containing the gene. Each gene
in turn is represented by a set of probes. From visual
inspection (Figure 1) it is clear that all these probes are
affected in a similar way by gene specific noise. An n ×
g binary 0/1 matrix Z indicates which of the n probes
represents each of the g genes and a vector u represents
gene specific noise levels. The information in the
matrices G and Z can be combined in a n × b binary
0/1 matrix X indicating for each of the b serotypes by
which of the n probes it is represented.
The response variables wj ≥ 0, 1 ≤ j ≤ n, are intensities
of the probes. A random effects ANOVA model is
wj = Xθ + Zu + εj
Where θ is a b-vector of the abundance of serotypes,
u is a g-vector of nuisance parameters for noise affecting
all probes of a gene in the same way, and ε is a noise
term for individual probes. Note that there is no mean
parameter and the entries in the matrix X are 0 or 1.
Hence θ is the vector of direct (nonnegative) abun-
dances of all serotypes in the sample. As priors we
assume θ ∼ N (0, cBBσ 2θ ), u ∼ N (0, cAAσ 2u ), and
ε ∼ N (0, Inσ 2e ), where A is a b × b matrix, B is a g × g
matrix, In is the unit matrix, and cB and cA are scaling
constants. The matrices A and B are fixed in advance,
while the scaling constants cB and cA are considered
hyperparameters. The matrix B is set to B = G’G, that
is, the more genes two serotypes have in common the
higher their abundance is assumed to correlate. Matrix
A is simply set to Ig. To enable the calculation of an
analytical solution for the posterior θ of via a conjugate
analysis and also to make the scaling constants cA and
cB identifiable, we assume σ 2θ = σ
2
u = σ
2
e . An inverse c
2
prior with degree ν0 = 10 and expected variance σ 20 is
assumed for σ 2e . Detailed derivations for this model are
provided in Additional file 2. Analysis of simulated data
showed that the hyperparameters cA, cB, ν0 and σ 20 are
best set in an empirical Bayes fashion by optimising the
marginal likelihood p
(
w|cAA, cBB, ν0, σ 20
)
.
Once a posterior distribution (a multivariate t distri-
bution, see Additional file 2) with mean θˆ for the sero-
type abundances θ is derived, an estimate of the
proportions of serotypes is provided by πi = θˆi/
∑
j
θˆj.
Due to our model assumptions θˆi can be negative, in
which case it is reset to 0. To obtain 95% credible inter-
vals for πi we draw 10000 samples θ
(k) from the poster-
ior of θ and obtain sample proportions
π (k)
i
= θ (k)i /
∑
j
θ
(k)
j . Credible (marginal) intervals for πi
are then easily obtained from the distributions of simu-
lated serotype proportions π (k)
i
.
Results and Discussion
Reference arrays
The analysis method gave a correct result for 88 of the
91 reference arrays. Prior parameter values were 1 =
13, a = 0.01, b = 0.01, g = 0.95. Three reference arrays,
testing serotypes 44, 25A and 37, appeared to give
incorrect results.
On the reference array testing serotype 44 the analysis
called serotype 12F as present, and on the array testing
25A, serotype 25F was called as present. These are two
pairs of closely related serotypes and therefore it is likely
that the probes designed to discriminate these were not
performing optimally or were targeting a poor region
for reliable differentiation. The array testing serotype 37
detected a combination of serotype 37 and serotype
33A. This is expected since serotype 37 contains a non-
functional copy of the cps gene complement of serotype
33A. Hence the Bayesian model does produce the cor-
rect call after all.
For the majority of the reference arrays the particular
serotype being tested in the array experiment had a
probability P(S | y, d) of effectively 1, the other 90 sero-
types having extremely low probabilities. For a few
arrays the serotype being tested had a probability mark-
edly lower than 1. Figure 5A shows a histogram of the
highest probability P(S | y, d) in the analysis of each of
the 91 reference arrays. The lower probabilities of a few
of the correct serotypes are due to the existence of
another serotype with a very similar cps gene comple-
ment, differing by just one gene.
Originally the model did not include cross-hybridisa-
tion. Without the inclusion of cross-hybridisation the
model still gives relatively good results, although three
more reference arrays gave incorrect calls. The array
testing serotype 24F called a combination of 24F and
24B, whilst the array testing 33A called 33F, and the
Newton et al. BMC Bioinformatics 2011, 12:88
http://www.biomedcentral.com/1471-2105/12/88
Page 10 of 16
array testing 7B called a combination of 7B and 7C. The
inclusion of cross-hybridisation solved these three pro-
blem serotypes.
Spike-in experiment
Analysis of the four samples in the spike-in experiment
gave the correct serotype combinations, with no false
positives and no false negatives. The parameter values,
1 = 13, a = 0.01, b = 0.01, g = 0.95, were the same as
used for the analysis of the reference arrays.
Table 3 gives the results for the spike-in experiment
and Figure 6 plots the measured percentage abundance
against the spiked-in percentage abundance. The esti-
mates of the percentage abundance of the serotypes in
the combinations agreed reasonably well with the actual
spiked-in percentages. The only exception is sample 2 in
table 3 where the estimate of the first component is
slightly too low. However, spike-in experiments with
exact amounts of the pathogen are difficult to perform;
that is the target numbers in the third column of table 3
are approximate only.
Influence of prior value 1
The results for the reference arrays in Figure 5A are for
a value of 1 = 13, which gives optimal results. In a clin-
ical context, however, not missing a serotype present in
a sample in only trace abundance is of importance. We
therefore provide a second choice of a high sensitivity
setting with 1 = 1 in the software implementation of
the analysis. Figure 5B shows a histogram of the highest
P(S | y, d) probability in the analysis of each of the 91
reference array experiments when 1 = 1. When 1 = 1
there are three extra apparent errors.
The array calling serotype 23F calls a combination of
serotypes 23F and 23B. These two serotypes have thir-
teen cps genes in common and five different. The five
differences are in cps genes which are closely related.
The extra sensitivity of the analysis with 1 = 1 is
detecting the five cps genes of serotype 23B. These have
levels slightly elevated from the background due in part
to cross-hybridisation from the corresponding five genes
in serotype 23F. Refinement of the cross-hybridisation
analysis may be able to resolve this problem, although
the fact that 23F and 23B are closely related means that
from a clinical stand point this false positive is not too
critical. In addition the software implementation of the
analysis carries out further checks. For each called sero-
type, the software checks the probabilities of that sero-
type’s genes (P(y | Gi = 1)). If any serotype’s genes have
P(y | Gi = 1) < 0.5 that serotype is flagged as such. In
this case serotype 23B is flagged as having genes with P
(y | Gi = 1) < 0.5, alerting users to the need for further
investigation.
The array testing serotype 33A now calls a combina-
tion of serotypes 33A & 29, and the array testing sero-
type 14 calls a combination of 14 & 19A. Serotypes 33A
and 29 are not closely related, with only one cps gene in
common. Similarly serotypes 14 and 19A are also unre-
lated with only one cps gene in common, so it was
thought unlikely that these incorrect calls were due to a
problem with the analysis. Further analysis indicates
that the genes for 29 and 19A are actually present in
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Figure 5 Reference arrays results . Histogram of the highest
probability P(S|y, d) in the analysis of each of the 91 reference arrays
for 1 = 13 (A) and 1 = 1 (B).
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Figure 6 Spike-in arrays results. Percentage abundance estimated
by the analysis plotted against the actual spiked-in percentage
abundance, from the spike-in experiment.
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very low relative abundance in the samples and we think
that these calls are due to contamination of samples
33A and 14 at some stage in the experimental process.
Eight microarrays are mounted on a single glass slide.
The arrays testing serotypes 14 and 19A were adjacent
on the glass slide so contamination of the sample con-
taining serotype 14 with serotype 19A at this stage of
the experiment is plausible. If the assumption of con-
tamination is correct, the setting of 1 = 1 seems to be
able to detect the presence of contaminating serotypes
at very low abundance levels.
For the spike-in experiment, with a value of 1 = 1 the
analysis still identified all the correct serotypes as being
present but, due to the higher sensitivity at this set-ting,
the analysis also gave some false positives (Sample 1:
19A, Sample 2: 19A, Sample 3: 19A, Sample 4: 23B). All
the false positives were flagged by the software as having
genes with P(y | Gi = 1) < 0.5, but none of the true
positives were flagged.
We recommend that users of the software implemen-
tation of the algorithm run the analysis twice. An initial
run with 1 = 13 will indicate the main serotype or ser-
otypes present in the sample. A second run with 1 = 1
will indicate if there may also be extra low abundance
serotypes present. If any of these serotypes have genes
with P(y | Gi = 1) < 0.5 they will be flagged, to alert the
user that they may warrant further investigation.
Influence of prior values a, b and g
The optimum values of a, b and g will vary with sero-
type being studied, so general values of the three priors
that work well for all serotypes were chosen, based on
expert estimates of expected true and false response
rates of probes, namely a = 0.01, b = 0.01, g = 0.95. The
suitability of the chosen values was investigated further.
Each reference array was analysed in turn. The values of
a, b and g that gave the highest value of P(Si | y) for the
serotype that the array was testing were found by
numerical optimisation. Figure 7 shows pairwise plots of
the optimum values for a, b and g for the 91 reference
arrays. Whilst there are some outliers the optimum
values for a, b and g for most serotypes cluster in
the region of the chosen values a = 0.01, b = 0.01,
1 -g = 0.05.
The sensitivity of the results to the values of a, b and
g was also investigated. The 91 reference arrays were
analysed in turn. Each array was analysed with all com-
binations of eight different values of a and b (0, 0.001,
0.005, 0.01, 0.02, 0.05, 0.1, 0.3) and g (1, 0.99, 0.975,
0.95, 0.9, 0.8, 0.7, 0.5). The effect of the prior values that
we are most interested in is not so much the absolute
value of P(S | y, d) for the serotype S being tested on
the array, but whether this probability is the highest on
that array. Therefore for each combination of prior
values the fraction of the 91 reference arrays that call
the correct serotype as the most probable serotype on
the array was recorded.
The results for a and b are presented in Figure 8. The
figure shows how the fraction of correctly called sero-
types varies with a and b (g being held at its default
value of 0.95). The default values of a = 0.01 and b =
0.01 lie within the optimal range to generate the maxi-
mum number of correctly called serotypes.
It can be seen from Figure 8 that values of b between
0 and 0.02 give the same results as the default of b =
0.01. b is the false negative rate for binding, allowing for
those genes that do not bind to their probes, despite a
serotype that contains those genes being present in a
sample. For the reference arrays, which test samples
containing only one serotype, the intensities of the
probes that should be present are sufficiently high for
this correction to be less important. The benefit of
including b = 0.01, arises when a sample contains a
combination of serotypes, some with low percentage
abundance. Then the intensities of some of the probes
that should be present will be much closer to the back-
ground noise (see Figure 2).
Whereas the value of g effects the value of P(Si | y),
the correct calling of the three serotypes that are influ-
enced by cross-hybridisation (24F, 33A and 7B) was
found to be insensitive to the values of g tested. As the
serotyping array develops in the future, as more closely
related serotypes of S. pneumoniae are discovered,
and more probes are added to the array, then cross-hybri-
disation may become a greater problem and it may be
necessary to adjust the value of g to give optimal results.
Conclusions
The Streptococcus pneumoniae molecular serotyping
microarray combined with an empirical Bayesian data
analysis presents two main advantages over conventional
methods for serotyping strains. Firstly, it is extremely
accurate in identifying the correct serotype in single sero-
type samples. Secondly, it has the ability to easily detect
combinations of serotypes within a sample. Initially we
tried a simpler analysis of the array data, based on fre-
quentist methods, in which p-values for individual genes
were calculated using t-tests and then combined. On the
reference arrays a p-value approach gave thirteen incor-
rect serotype calls, an unacceptably high error rate, so
the current Bayesian model was adopted. The empirical
Bayesian data analysis does give two incorrect serotype
calls for closely related pairs of serotypes, but these errors
have been identified as design problems with the array
rather than a problem with the analysis, a de-sign pro-
blem that will be addressed in future releases of the array.
The Bayesian approach enables additional information,
such as on cross-hybridisation or on STIDs, to be
Newton et al. BMC Bioinformatics 2011, 12:88
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integrated into the main model. The method does not
require accurate estimates of prior parameters, working
well with general estimates of these values for all sero-
types. A few hyperparameters are estimated from the
data in an empirical Bayes fashion, but in a way that is
independent of knowledge of present serotypes or com-
binations of serotypes. The prior parameters were cho-
sen to be standardised and repeatable across arrays,
where levels of signal or background intensity can
change. For the reference arrays the signal in the data is
reasonably strong. However, for the low percent-age
abundance serotypes in the spike-in arrays the signal to
noise ratio is much lower, but the same prior parameter
values work well.
The spike-in experiment indicates that the method
can detect multiple serotypes in samples with as large a
number of serotypes as is ever likely to be found in a
clinical setting. Serotypes with very low abundance
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Figure 7 Optimum values of a, b and 1 -g. Pairwise plots of the optimum values (log10) of a, b and 1 -g. Each point represents the optimum
values of a, b and 1 -g for one of the reference arrays. The crosses mark the positions of the actual values of a, b and 1 -g used in the analysis
(a = 0.01, b = 0.01 and 1 -g = 0.05).
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within a combination can be detected by the method. As
well as detecting the presence of serotype combinations,
an approximate measure of the percentage abundance of
the serotypes within the combination can be obtained.
Of the 16 estimated abundances in table 3, one serotype
(19F in sample 2) lies slightly outside the credible inter-
val. Further experimental work will be required to deter-
mine whether this is a problem with the statistical
analysis or has arisen from experimental imprecision in
the creation of this particular spike-in sample. However
the overall conclusions from the results to date suggest
that as well as the molecular serotyping microarray’s
primary role as a method for calling serotypes, it can
also provide a useful indication of serotype relative
abundance.
In this article we have proposed two separate models.
The first is for calculating posterior probabilities of
combinations of serotypes where only presence or
absence of serotypes is considered. The second model
estimates the relative abundance of serotypes. In
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Figure 8 Influence of a and b on fraction of correctly called serotypes. Surface plot showing how the fraction of correctly called serotypes
in the reference array data set varies with the values of priors a and b.
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principle the two models could be combined. However,
the primary clinical interest is in calling presence or
absence of serotypes. Their quantitative assessment is of
secondary interest. A model comprising both would be
more complex and might compromise the performance
as a serotype caller.
The linear Gaussian model with constant variances for
estimating relative abundances of serotypes makes
assumptions which are certainly only approximately cor-
rect. For example, abundances are always positive and
variances will depend on the abundance values. However,
in simulations and in the analysis of the spike-in data this
model performed considerably better than simpler mod-
els without integration over variances or over the hidden
gene abundances. That is, under the constraint of having
a model that can be solved analytically, which is impor-
tant when analysing larger data sets interactively as is
currently done with the present software, the current
model is an excellent approximation.
This algorithm has been applied to over one thousand
clinical samples, containing both single serotypes and
combinations of serotypes. The cps gene content of
these samples have been checked by manual data analy-
sis methods which has confirmed that the technique
described in this article is a reliable automatic analysis
method for the S. pneumoniae molecular serotyping
microarray. The inference could be affected by the heur-
istic we employ to reduce the number of combinations
tested to a computationally feasible level. Increasing the
number of combinations tested does not produce any
extra combinations of serotypes that have a non-
negligible probability, when applied to the clinical data
or the reference and spiked-in arrays, indicating that the
current cut-off is quite generous.
In this Bayesian method to analyse the S. pneumo-
niae molecular serotyping microarray the serotype
combination with the highest probability is accepted as
the answer. Alternatively, probabilities for properties of
interest, for example, the co-occurrence of specific ser-
otypes, may be obtained by model averaging, that is,
by summing probabilities of the corresponding sero-
type combinations. The method is also easily extensible
as more is learned of the different strains of this
important pathogen. The use of diagnostic microarrays
is not confined to the field of infectious diseases. For
example arrays have been used as potential diagnostic
tools in oncology [13] and cytogenetics [14]. The sta-
tistical analysis method is quite general and is easily
adapted for other diagnostic microarrays that use
similar technology. The Bayesian approach means
that if these microarrays contain extra features, they
can be incorporated into the analysis with minimal
modification.
An alternative solution to the problem of cross-hybridi-
sation would be to reannotate the cps gene com-positions
of the serotypes. The advantage of our approach is that
the invariant biological input to the model, that is the cps
gene complements of the serotypes determined experi-
mentally by sequencing is separate from the cross-hybridi-
sation input which is a design issue with the array and
may not be invariant. The array is being constantly revised
and improved so the Bayesian model keeps separate the
information that will not change from the information
that may change in the future.
The method as it stands works very well. Future work
will concentrate on solving problems that may arise as
further data sets become available. Adding prior infor-
mation on gene specific variances and STID specific var-
iances will be investigated as a method for improving
the accuracy of the analysis [15]. In general cross-
hybridisation is not a problem due to careful probe
design. Where it is a problem the current model treats it
at the gene rather than at the probe level. Dealing with
cross-hybridisation at the probe level may improve the
model. However, cross-hybridisation is only a problem
between some of the homologous genes, which are very
similar in sequence. This means that most of the genes’
probes do cross-hybridise, so treating cross-hybridisation
at the probe level may not significantly improve perfor-
mance. An advantage of the current approach is that it is
essentially analytical so works well without the need for
expert input, and is not too computationally intensive.
But the potential of more complex models that require a
sampling approach should also be investigated.
The algorithms described in this paper were imple-
mented in the R statistical system [11]. For the benefit
of researchers in the field of S. pneumoniae who are
unfamiliar with R, a user friendly web interface was cre-
ated for the R script. This web interface was created
using the web application Rwui [16].
Additional material
Additional file 1: Distributions and posteriors. Equations and
derivations for all distributions used in calculating the probabilities of
combinations of serotypes.
Additional file 2: Bayesian Anova. Equations and derivation of the
Bayesian Anova.
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